Highlighted Research Initiatives
The Accelerating Medicines Partnership® program - Schizophrenia (AMP® SCZ) is a public-private partnership that aims to generate tools that will considerably improve success in developing early-stage interventions for patients who are at risk of developing schizophrenia.
EPINET is a broad research initiative aimed at determining how to best provide treatment for individuals experiencing symptoms of early psychosis. The network includes regional hubs and more than 100 clinics across the country that provide Coordinated Specialty Care (CSC), a multi-component treatment for early psychosis.
Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY)
The Advanced Laboratories for Accelerating the Reach and Impact of Treatments for Youth and Adults with Mental Illness (ALACRITY) Research Center program aims to support innovative research ideas and transdisciplinary collaborations that could transform the care of children, adolescents, and adults with severe psychiatric disorders.
In April 2018, NIH launched the HEAL (Helping to End Addiction Long-termSM) Initiative, an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis.
RAPID is promoting the development of speedier therapies for severe, treatment-resistant depression through the creation of a research team tasked with identifying and testing promising pharmacological and/or non-pharmacological treatments that lift depression within a few days, instead of weeks or months.
ABCD is a landmark study on brain development and child health led by the Collaborative Research on Addiction at National Institutes of Health (NIH). This project aims to increase the understanding of environmental, social, genetic, and other biological factors that affect brain and cognitive development and that can enhance or disrupt a young person’s life trajectory.
The FAST initiative aimed to provide a quick way to test new or repurposed compounds for their potential as psychiatric medications. Using small clinical trials, FAST quickly identified whether the study compounds hit intended targets in the brain, and those that did were identified for further research.
Army STARRS was the largest study of mental health risk and resilience ever conducted among military personnel. The goal of the project was to identify, as rapidly as possible, risk and protective factors that can help the Army develop effective strategies to reduce rising suicide rates and address associated mental health problems among soldiers.
RAISE was a large-scale research project exploring whether early, targeted, and aggressive treatment can reduce symptoms and prevent the gradual deterioration of functioning characteristic of chronic schizophrenia. RAISE research helped lead to the formation of EPINET.